Browse the corpus

Desipramine is a tricyclic antidepressant (TCA) used in the treatment of depression and occasionally prescribed for off-label conditions such as neuropathic pain, irritable bowel syndrome, and postherpetic neuralgia. Despite its therapeutic benefits, its clinical use has declined because of safety concerns that include anticholinergic adverse effects, cardiovascular toxicity, seizure risk, and an increased risk of suicidality in younger individuals. Additional challenges in therapy arise from CYP2D6-related metabolic variability and multiple potential drug–drug interactions that may alter drug levels or increase toxicity. Although not commonly used as first-line therapy, healthcare professionals may still encounter desipramine in treatment-resistant depression or selected off-label situations. These circumstances highlight the importance of maintaining clinical familiarity with TCA pharmacology and safety considerations. This activity provides a focused review of desipramine’s pharmacologic properties, therapeutic indications, adverse-effect profile, and recommended monitoring practices. Participants will strengthen their ability to evaluate patient-specific risks, recognize potential drug interactions, and identify early signs of toxicity or overdose. The activity also highlights the importance of interprofessional collaboration among healthcare providers to promote safe prescribing practices and improve outcomes for patients receiving TCA therapy. Objectives: Identify the pharmacologic mechanism, approved indications, and common off-label uses of desipramine relevant to clinical practice. Screen patients receiving desipramine for adverse effects, emerging toxicity, and worsening depression or suicidal ideation during treatment. Determine appropriate monitoring strategies, including clinical assessment and follow-up intervals, for patients receiving desipramine. Collaborate with members of the interprofessional healthcare team to address complex patient needs. Access free multiple choice questions on this topic.

Signs and Symptoms of Overdose Desipramine is associated with a higher mortality compared to other TCAs.[24] Overdose of desipramine may result in cardiac dysrhythmia, severe hypotension, convulsions, comatose state, hyperactive reflexes, stupor, drowsiness, hypothermia, and confusion.[25] Serotonin syndrome results from excessive serotonergic activity. Combining antidepressants with MAOIs can cause serotonin syndrome. Signs and symptoms of serotonin syndrome include hyperthermia, agitation, dilated pupils, tremors, akathisia, muscle rigidity, increased bowel sounds, flushed skin, and diaphoresis. Management of Overdose First-line treatment of acute toxicity includes supportive care, serum alkalinization, electrocardiographic monitoring, and gastric decontamination. Patients should be observed for at least 6 hours for symptoms such as unexplained syncope, shortness of breath, palpitations, and chest pain. Gastrointestinal decontamination with activated charcoal should be initiated as soon as possible. Emesis is contraindicated in desipramine toxicity. In patients with serotonin syndrome, management consists of supportive care and serotonin antagonists such as cyproheptadine. Please see StatPearls' companion resource, "Tricyclic Antidepressants," for more information. If the QRS duration exceeds 100 milliseconds, intravenous sodium bicarbonate should be initiated.[26] Seizures should be treated with benzodiazepines.[27] Lipid emulsion therapy may be considered in refractory cases in consultation with a toxicologist.[28][29] Further research is needed to clarify the role of lipid emulsion therapy in TCA overdose.

Desipramine is a secondary amine TCA approved for the treatment of major depressive disorder, although it is no longer considered first-line therapy because of its adverse effects and toxicity profile. The drug primarily inhibits presynaptic reuptake of norepinephrine and, to a lesser extent, serotonin, increasing neurotransmitter availability within the synapse and contributing to its antidepressant and antinociceptive effects. Off-label uses include neuropathic pain, postherpetic neuralgia, irritable bowel syndrome, overactive bladder, bulimia nervosa, and ADHD. Desipramine is extensively metabolized by hepatic CYP2D6, and genetic polymorphisms may produce substantial variability in drug concentrations and clinical response. Clinicians must also consider cardiovascular risk, anticholinergic effects, and the potential for suicidality in younger patients. Careful monitoring, gradual dose titration, and attention to drug-drug interactions are essential to minimize toxicity. Interprofessional collaboration improves safety and therapeutic outcomes during desipramine therapy. Physicians, psychiatrists, primary care clinicians, and advanced practice providers evaluate indications, screen for cardiac risk, and determine appropriate dosing and monitoring strategies. Pharmacists assess potential drug interactions, evaluate CYP2D6-related risks, verify dosing, and counsel patients on adherence and toxicity. Nurses monitor for adverse effects, reinforce medication education, and observe for clinical deterioration or emergent suicidality. Coordinated communication among team members supports early recognition of complications, timely dose adjustment or referral, and shared decision-making with patients and caregivers, thereby enhancing treatment safety and overall quality of care.